Mesenchymal Stem-Cell-Derived Exosomes and MicroRNAs: Advancing Cell-Free Therapy in Systemic Sclerosis
Cells · 03.07.2025 · 14 (13) · 1018
DOI: 10.3390/cells14131018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 03.07.2025. Verfasst von Cristiano Barbetta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, AOU Careggi, 50121 Florence, Italy. Hauptthemen laut MEDLINE: Exosomes, Scleroderma, Systemic, MicroRNAs, Mesenchymal Stem Cells. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mesenchymal stem cell (MSC) transplantation has emerged as a potential therapeutic strategy for systemic sclerosis (SSc), a rare autoimmune disease characterized by inflammation, fibrosis, and vasculopathy. Recent evidence suggests that the therapeutic benefits of MSCs do not depend directly on their ability to proliferate but rather on their capacity to release extracellular nanovesicles known as exosomes (MSC-Exos). MSC-Exos are rich in bioactive molecules such as microRNAs, which can modulate gene expression and trigger significant biological responses, playing a central role in modulating immune responses, inhibiting fibrotic pathways and promoting tissue repair and angiogenesis. Preclinical studies have demonstrated that MSC-Exos can attenuate fibrosis, modulate macrophage polarization, suppress autoreactive lymphocyte activity, and even reverse pulmonary arterial hypertension in animal models of SSc. Compared to cell-based therapies, MSC-Exos offer several advantages, including lower immunogenicity and better safety profile. This review provides an overview of the immunomodulatory, antifibrotic, and angiogenic properties of MSC-Exos and explores their potential as novel cell-free therapy for SSc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, AOU Careggi, 50121 Florence, Italy.
- Department of Internal Medicine, University Hospital Careggi, 50134 Florence, Italy.
- Southern California Scleroderma and Rheumatology Centre, Los Angeles, CA 90095, USA.
ORCID-Profile: Francesco Bonomi, Silvia Bellando Randone, Serena Guiducci
Zitieren
APA
Barbetta, C., Bonomi, F., Lepri, G., Furst, D. E., Randone, S. B., & Guiducci, S. (2025). Mesenchymal Stem-Cell-Derived Exosomes and MicroRNAs: Advancing Cell-Free Therapy in Systemic Sclerosis. Cells, 14(13), 1018. https://doi.org/10.3390/cells14131018
Vancouver
Barbetta C, Bonomi F, Lepri G, Furst DE, Randone SB, Guiducci S. Mesenchymal Stem-Cell-Derived Exosomes and MicroRNAs: Advancing Cell-Free Therapy in Systemic Sclerosis. Cells. 2025;14(13):1018. doi:10.3390/cells14131018
BibTeX
@article{Barbetta2025,
author = {Barbetta, Cristiano and Bonomi, Francesco and Lepri, Gemma and Furst, Daniel E and Randone, Silvia Bellando and Guiducci, Serena},
title = {Mesenchymal Stem-Cell-Derived Exosomes and MicroRNAs: Advancing Cell-Free Therapy in Systemic Sclerosis},
journal = {Cells},
year = {2025},
volume = {14},
number = {13},
pages = {1018},
doi = {10.3390/cells14131018}
}
EUVIMED